ClinicalTrials.gg
RecruitingNCT07067658ME-HFUpdated Jul 28, 2026

Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk

An interventional study of Installation of Heartfelt Device and Enhanced Standard care in Heart Failure, sponsored by Heartfelt Technologies. Recruiting at 18 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Heartfelt Technologies · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.

Planned enrollment
106th of 314
300 · median 120
Started
2025
with 25 others
No phase
146 of 482
32 open now
Primary completion
2026-12
later than 50 of 126 live
Registered
454th of 482
by date

Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 106th largest by planned enrollment of the 314 interventional ones that give a count, is one of 26 that started in 2025, is one of 146 with no phase, reaches primary completion later than 50 of the 126 other live ones, and was the 454th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:

94 more — sign in →

All 100 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Heart Failure with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this device, when added to standard NHS care, improves quality of life and reduces heart failure-related events compared to standard care alone.

Read the detailed description

Heart failure often causes fluid build-up in the legs and lungs, leading to symptoms like swelling and breathlessness. Spotting these signs early is important to help prevent worsening health and hospital admissions. While patients are encouraged to monitor their weight and symptoms, this can be hard to keep up with.

The study will involve 300 participants from at least 15 NHS hospitals and GP practices across the UK. People will be randomly placed into one of two groups: one will receive standard NHS care (including regular weight checks and symptom monitoring), and the other will receive the same care plus the Heartfelt device. The trial is partly blinded: participants may see technical messages (e.g. if the device goes offline), but only the group using the device will trigger clinical alerts.

The Heartfelt device takes daily images of the feet to track changes in size, without the need for any extra effort from the user. If important changes are spotted, alerts are sent to the clinical team so they can act quickly.

The study will look at quality of life, how often the device sends useful data, healthcare use, and how teams respond to alerts. It will also explore how easy the device is to use and whether it offers good value for money.

Patients will help shape the study to make sure the findings are relevant and useful for future care.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Peripheral Oedema
  • Heart Failure Decomposition
  • Heart Failure Hospitalization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants are eligible if they meet all General Criteria and at least one of Pathways A, B, or C.

1. General Criteria (all participants must meet)

  • Aged ≥18 years, AND
  • Diagnosis of heart failure (any aetiology or classification), AND
  • Documented or patient-reported moderate to severe leg oedema, AND
  • Lives in the UK with a home environment suitable for installation of the Heartfelt device

Pathway A: High risk patient with daily diuretics

  • Currently prescribed ≥40 mg/day of furosemide (or equivalent loop diuretic, eg. bumetanide or torsemide) for at least one month, AND
  • Any cardiorespiratory admission** in the last 12 months (Includes outpatient IV diuretics, subcutaneous loop diuretics, or escalation to combination therapy with a loop diuretic and a thiazide or thiazide-like diuretic (eg: metolazone, bendroflumethiazide, indapamide etc).

Pathway B: High risk patient without daily diuretics

  • Patients prescribed SGLT2 inhibitor (eg; dapagliflozin or empagliflozin) , AND
  • Patients prescribed oral furosemide ≥40mg/day but advised to take it only as needed AND either:

    a) at least two admissions* caused or complicated by worsening heart failure in the previous 12 months, OR b) a measurement of plasma NT-proBNP exceeding 1,000 ng/L (pg/mL) in the previous 12 months Pathway C: Implanted Haemodynamic Monitoring Devices (minimum n=10 participants)

  • Uses an implantable device designed to monitor congestion (e.g. CardioMEMS, HeartLogic, or equivalent)
  • Enrichment criteria: Patients must also meet a minimum total score of 4 from the characteristics below.

    1. class III and IV (score: 2)
    2. ≥80 mg/day Furosemide or equivalent loop diuretic (score: 2)
    3. \<3 Number of times the patient has weighed themselves in the last 2 weeks (score: 2)
    4. Help for essential daily activities required (score: 2)
    5. GRMT score \<5 (score: 2)
    6. Use of a walking stick, walker or mobility scooter (score: 2)
    7. >2 Number of HF events in last 12 months (score: 2)
    8. Aged over 75 (score: 1)
    9. Health issues limiting daily activities (score: 1)
    10. Help getting to medical appointment required (score: 1)
    11. Problematic / not tolerated uptitration of medications:

      MRA (score: 1) SGLT2i (score: 1) Other (score: 1)

    12. English as a second language (score: 1)
    13. 20-45 (score: 1)
    14. Patient unable to regularly attend appointments for any reason (score: 1)
    15. >3 Number of co-morbidities (score: 1)

Exclusion Criteria:

  • Amputation of both feet
  • Bed-bound for more than 20h per 24h period
  • Bandages to lower limbs every day
  • Regular wheelchair user inside their home
  • No fixed abode
  • Participation in another interventional trial that may interfere with endpoints
  • \<6 months, in the opinion of the investigator
  • Inability to provide due to cognitive impairment
  • Language barriers that preclude understanding of trial procedures (unless translation resources are available in relevant language)
  • Inability to install the device (even with assistance) allowing at least 6 months of data capture by the end of the study.
  • Patients with severe aortic stenosis or awaiting a heart procedure or surgery
  • Patient with end stage renal disease (eGFR \<20)
  • Pregnancy or lack of measures if of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Enhanced Standard Care + Heartfelt Device

    Heartfelt device's camera-based system passively measures foot and leg swelling each day as participants walk past it. Patients in this experimental control arm will not receive health alerts from the Heartfelt device, though data will still be passively collected. Patients will also be provided with the British Heart Foundation patient booklet to improve their understanding and self-monitoring of the disease.

    Device: Installation of Heartfelt Device · Other: Enhanced Standard care · Other: Questionnaires · Device: Heartfelt device alerting system

  • Active comparator
    Enhanced Standard Care (Control)

    In addition to standard care activities, participants have the Heartfelt device at home. During this arm, data is captured without sending health alerts or measurement data to the patient, carers and clinicians. Patients will also be provided with the British Heart Foundation patient booklet to improve their understanding and self-monitoring of the disease.

    Device: Installation of Heartfelt Device · Other: Enhanced Standard care · Other: Questionnaires

Interventions

  • DeviceInstallation of Heartfelt Device

    Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

    Also known as: Remote Patient Monitoring Device

  • OtherEnhanced Standard care

    Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation. At the start of the study, they will be reminded (or told) about the importance of self-checks and will be handed a patient booklet (from the British Heart Foundation) to standardise patients' knowledge.

    Also known as: Daily Weighing, Breathlessness, Dizziness, Tiredness

  • OtherQuestionnaires

    Patients are presented with one or more optional questionnaires (some validated, some bespoke)

    Also known as: 5Q-5D, Bespoke Questionnaires

  • DeviceHeartfelt device alerting system

    The Heartfelt device sends alerts on the active comparator arm to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.

    Also known as: Remote patient monitoring device

06

What researchers measure

Primary outcomes

  1. Composite Clinical Events

    Unplanned hospital attendance (clinic, emergency, or admission) or death due to heart failure, cardiovascular, respiratory, or renal causes. Recurrent events will be included and adjudicated, providing a comprehensive measure of clinical deterioration over 12 months.

    Time frame: Over 12-months period.

  2. Health-Related Quality of Life (EQ-5D-5L)

    Patient-reported quality of life measured using EQ-5D-5L, collected at baseline and follow-up (3, 6, 9, 12 months), with primary analysis at 12 months. This validated instrument captures overall health status across five domains and includes a visual analogue scale. * Measured using the EQ-5D-5L index * Collected at baseline, 3, 6, 9, and 12 months. * Primary time point: 12 months. EQ-5D-5L responses will be converted to utility scores on a scale from -0.59 to 1, where 1 represents the best health state, using the UK EQ-5D-5L value set. Patients with at least two or more utility scores during follow-up will be included in the analysis.

    Time frame: Collected at baseline, 3, 6, 9, and 12 months

Secondary outcomes

  1. Days Lost to Hospitalisation or Death

    Total number of days lost due to hospitalisation for cardiovascular, respiratory, or renal conditions, or due to all-cause mortality.

    Time frame: Over 12-months period.

  2. Daily Data Availability

    Proportion of days with successful data capture from the Heartfelt device and weighing scales, based on device-generated records or contemporaneous self-report.

    Time frame: Over 12-months period.

  3. Guideline-Recommended Medication Score

    Adherence to guideline-recommended heart failure medications will be assessed using a guideline-recommended medication score, calculated at 3, 6, 9, and 12 months and averaged across these time points. The score is based on the number of eligible medication classes prescribed, with 1 point assigned per class (e.g., ACEi/ARB/ARNI, beta-blocker, mineralocorticoid receptor antagonist \[MRA\]). The score ranges from 0 to 3, with 3 being the optimal medication score. The score is adjusted for patient eligibility: will be calculated only for patients with heart failure with reduced ejection fraction (HFrEF).

    Time frame: Over 12-months period.

  4. All-Cause Hospitalisations

    Number of hospitalisations from any cause, analysed as recurrent events and adjusted for the competing risk of death.

    Time frame: Over 12-months period.

  5. Loss of Independence or Mortality

    Composite measure of new admission to a long-term care facility or all-cause mortality.

    Time frame: During the 12-month trial period.

  6. Death and Cause of Death

    Classification of all deaths recorded during the trial as heart failure-related, other cardiovascular, or non-cardiovascular causes, based on clinical records.

    Time frame: During 12-months trial period.

07

Study locations

15 of 18 sites recruiting
  • Buckinghamshire Healthcare NHS Trust
    Aylesbury, Buckinghamshire HP21 8AL, United Kingdom
    Recruiting
  • Croydon Health Services NHS Trust
    Croydon, Greater London CR7 7YE, United Kingdom
    Recruiting
  • Hertfordshire Community NHS Trust
    Welwyn Garden City, Hertfordshire AL7 1BW, United Kingdom
    Recruiting
  • Holderness Health
    Patrington, Hull HU120PH, United Kingdom
    Recruiting
  • Kent Community Health NHS Foundation Trust
    Ashford, Kent TN25 4AZ, United Kingdom
    Recruiting
    • Charlotte Marlow · Contactme-hf.trial@hftech.org · 01987252381
    • Jacqueline Sinnott · Principal investigator
  • Lincolnshire Community Health Services NHS Trust
    Lincoln, Lincolnshire LN5 7JH, United Kingdom
    Recruiting
  • North Tees & Hartlepool NHS Foundation Trust
    Hardwick, Stockton-on-Tees TS19 8PE, United Kingdom
    Recruiting
  • Ulster Hospital
    Belfast, BT16 1RH, United Kingdom
    Not yet recruiting
    • Dr Patrick Donnelly · Contactme-hf.trial@hftech.org · 028 9048 4511
    • Patrick Donnelly, Dr · Principal investigator
  • Princess of Wales Hospital
    Bridgend, CF31 1RQ, United Kingdom
    Recruiting
    • Gabby Williams · Contactme-hf.trial@hftech.org · 01443 443443
    • Aaron Wong, Dr · Principal investigator
    • Gabby Williams · Sub investigator
  • Queen Elizabeth University Hospital (NHS Greater Glasglow & Clyde)
    Glasgow, G51 4TF, United Kingdom
    Recruiting
    • Pierpaolo Pellicori, Dr · Contactme-hf.trial@hftech.org · 01412327599
    • Pierpaolo Pellicori, Dr · Principal investigator
  • Hull University Teaching Hospitals NHS Trust
    Hull, HU3 2JZ, United Kingdom
    Not yet recruiting
    • Joe Cuthbert · Contactme-hf.trial@hftech.org · 01482 875875
    • Joe Cuthbert, Dr · Principal investigator
    • Elton Luo, Dr · Sub investigator
  • St George's Hospital
    London, SW17 0QT, United Kingdom
    Recruiting
    • Sinead Lyons · Contactme-hf.trial@hftech.org · 02087254404
    • Robin Ray, Dr · Principal investigator
    • Sinead Lyons · Sub investigator
  • Manchester University NHS Foundation Trust
    Manchester, M13 9WL, United Kingdom
    Recruiting
  • Milton Keynes University Hospital NHS Foundation Trust
    Milton Keynes, MK6 5LD, United Kingdom
    Recruiting
  • Chilwell Valley and Meadows Practice
    Nottingham, NG9 6DX, United Kingdom
    Recruiting
  • Livewell Southwest
    Plymouth, PL6 5DH, United Kingdom
    Not yet recruiting
  • Royal Glamorgan Hospital
    Pont-y-clun, CF72 8XR, United Kingdom
    Recruiting
    • Aimee Ibbotson · Contactme-hf.trial@hftech.org · 01443 443443
    • Karen Knight · Contact01443 443443
    • Aimee Ibbotson · Principal investigator
  • Walsall Manor Hospital
    Walsall, WS2 9PS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) will only be shared if approved by the Trial Management Group and that suitable ethics approvals has been received for sharing of such information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 12 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 16, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 31, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07067658
Lead sponsor
Heartfelt Technologies
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Dec 18, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Oriane Chausiaux
Contact
me-hf.trial@hftech.org
01223967250

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion